TERAPIA FÁGICA: UMA ABORDAGEM INOVADORA NO TRATAMENTO DE INFECÇÕES POR BACTÉRIAS RESISTENTES
DOI:
https://doi.org/10.47820/recima21.v6i2.6264Palavras-chave:
Bacteriófagos, Terapia Fágica, Resistência Bacteriana, AntibióticosResumo
Dentre as problemáticas da infectologia, na atualidade, a resistência bacteriana a antibióticos se apresenta como uma ameaça expressiva à saúde populacional, principalmente no quesito de tratamento de infecções. Assim, em uma era de resistência antibiótica, os bacteriófagos se tornam um produto terapêutico em potencial contra infecções. Os bacteriófagos são vírus que infectam bactérias com alta especificidade e também podem ser projetados utilizando engenharia genética para exterminar cepas resistentes a antibióticos. No mínimo 1 milhão de pessoas por ano são acometidas por infecções resistentes no Brasil, as bactérias mais preocupantes são Klebsiella pneumoniae, Escherichia coli e Acinetobacter baumanii. A terapia com fagos pode ser dividida em duas principais abordagens: a personalizada e a não personalizada, sendo que a primeira possui melhores resultados. Os fagos demonstraram ser bem tolerados e seguros, independentemente da via utilizada. Contudo, os ensaios clínicos ainda carecem de sistematização completa da metodologia, sendo crucial promover e investir em ensaios clínicos bem estruturados para garantir melhores resultados aos pacientes.
Downloads
Referências
ABEDON, S. T. Information Phage Therapy Research Should Report. Pharmaceuticals, [S. l.], v. 10, n. 2, abr. 2017. DOI: 10.3390/ph10020043. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490400/. Acesso em: 06 set. 2024.
ADVOCATING for phage therapy. Nature Microbiology, [S. l.], v. 9, p.1397–1398, jun. 2024. DOI: https://doi.org/10.1038/s41564-024-01733-7. Disponível em: https://www.nature.com/articles/s41564-024-01733-7#article-info. Acesso em 20 set. 2024.
ALEKSHUN, M. N.; LEVY, S. B. Molecular Mechanisms of Antibacterial Multidrug Resistance. Cell, [S. l.], v. 23, n.128, p.1037-1050, mai. 2007. DOI: 10.1016/j.cell.2007.03.004. Disponível em: https://www.cell.com/action/showPdf?pii=S0092-8674%2807%2900311-X. Acesso em: 2024.
ANTIMICROBIAL RESISTANCE COLLABORATORS. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, [S. l.], v. 399, p. 629-655, fev. 2022. DOI: 10.1016/S0140-6736(21)02724-0. Disponível em: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext. Acesso em: 26 ago. 2024.
ANVISA - AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Confira dados mundiais sobre resistência microbiana. Brasilia: ANVISA, 23 nov. 2021. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/confira-dados-mundiais-sobre-resistencia-microbiana. Acesso em: 17 mar. 2024.
BALASUBRAMANIAN R. et al. Global incidence in hospital-associated infections resistant to antibiotics: An analysis of point prevalence surveys from 99 countries. PLoS Medicine, [S. l.], v. 20, n. 6, jun. 2023. DOI: doi.org/10.1371/journal.pmed.1004178. Disponível em: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004178. Acesso em: 30 ago. 2024.
BANCO MUNDIAL. Drug-Resistant Infections: A Threat to Our Economic Future. Washington, DC: World Bank, 2017. Disponível em: https://www.worldbank.org/en/topic/health/publication/drug-resistant-infections-a-threat-to-our-economic-future. Acesso em: 06 set. 2024.
BRAGG, R. et al. First International Conference, Advances in Experimental Medicine and Biology. Bacteriophages as potential treatment option for antibiotic resistant bactéria, New Delhi, v. 807, p. 97-110, 2014. DOI: 10.1007/978-81-322-1777-0_7. Disponível em: https://pubmed.ncbi.nlm.nih.gov/24619620/. Acesso em: 04 mar. 2024.
BRIVES, C.; POURRAZ, J. Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun, [S. l.], v. 6, n. 100, p. 1-11, 2020. DOI: https://doi.org/10.1057/s41599-020-0478-4. Disponível em: https://www.nature.com/articles/s41599-020-0478-4#citeas. Acesso em: 25 jun. 2024.
CDC - CENTERS FOR DISEASE CONTROL AND PREVENTION. Antibiotic resistance threats in the United States. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. Disponível em: http://dx.do.i.org/10.15620/cdc:82532. Acesso em: 30 ago. 2024.
CHEVALLEREAU, A. et al. Interactions between bacterial and phage communities in natural environments. Nat. Rev. Microbiol, [S. l.], v. 20, n. 1, p. 49-62, jan. 2022. DOI: 10.1038/s41579-021-00602-y. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34373631/. Acesso em: 18 maio 2024.
CLOKIE, M. R. et al. Phages in nature. Bacteriophage, [S. l.], v. 1, n. 1, p. 31-45, jan. 2011. DOI: 10.4161/bact.1.1.14942. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109452/. Acesso em: 01 mai. 2024.
COHEN, N. Antibiotic resistance: a battle of wits versus natural selection. [S. l.], Harvard University, 2011. Disponível em: https://sitn.hms.harvard.edu/flash/2011/issue103/ Acesso em: 28 maio 2024.
CONLY, J.; JOHNSTON, B. Where are all the new antibiotics? The new antibiotic paradox. Canadian Journal of Infectious Diseases and Medical Microbiology, [s.l.], v. 16, n.3, p. 159-160, mai. 2005. DOI: 10.1155/2005/892058. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095020/. Acesso em: 04 mar. 2024.
DEDRICK, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nature Medicine, [S. l.], v. 25, n. 5, p. 730-733, mai. 2019. DOI: 10.1038/s41591-019-0437-z. Disponível em: https://www.nature.com/articles/s41591-019-0437-z. Acesso em: 26 ago. 2024.
D'HERELLE, F. Bacteriophage as a Treatment in Acute Medical and Surgical Infections. Bull New York Academy of Medicine. New York, v. 7, n. 5, p. 329-348, mao 1931. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095997/?page=1. Acesso em: 06 ago. 2024.
FEDOROV, E. et al. Short-Term Outcomes of Phage-Antibiotic Combination Treatment in Adult Patients with Periprosthetic Hip Joint Infection. Viruses, [S. l.], v, 15, n. 2, p. 499, fev. 2023. DOI: 10.3390/v15020499. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36851713/. Acesso em: 14 out. 2024.
FLEMING, A. Chemotherapy: Yesterday, To-Day, and To-Morrow. Cambridge: Cambridge University Press, 1946. p. 39.
FRIEDEN, T. Centers for Disease Control and Prevention. Antibiotic resistance threats. United States: Department of Health and Human Services; 2013. Disponível em: https://www.cdc.gov/antimicrobialresistance/media/pdfs/arthreats2013508.pdf?CDC_AAref_Val=https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Acesso em:17 mar. 2024.
GENCAY, Y. E. et al. Engineered phage with antibacterial CRISPR–Cas selectively reduce E. coli burden in mice. Nature Biotechnology, [S. l.], v. 42, p. 265–274, fev. 2024. DOI: https://doi.org/10.1038/s41587-023-01759-y. Disponível em: https://www.nature.com/articles/s41587-023-01759-y. Acesso em: 06 set. 2024.
GOODRIDGE, L.; ABEDON, S. T. Bacteriophage biocontrol and bioprocessing: Application of phage therapy to industry. SIM News, [S. l.], v. 53, n. 6, p. 254-262, nov./dez. 2003. Disponível em: https://www.researchgate.net/publication/242411977_Bacteriophage_biocontrol_and_bioprocessing_Application_of_phage_therapy_to_industry. Acesso em: 26 mar. 2024.
HATFULL, G. F.; DEDRICK, R. M; SCHOOLEY, R. T. Phage Therapy for Antibiotic-Resistant Bacterial Infections. Annual Review of Medicine, [S. l.], v. 73, n. 27 p.197-211, jan. 2022. DOI: 10.1146/annurev-med-080219-122208. Disponível em: https://www.annualreviews.org/content/journals/10.1146/annurev-med-080219-122208#right-ref-B1. Acesso em: 10 abr. 2024.
HITCHCOCK, N. M. et al. Current Clinical Landscape and Global Potential of Bacteriophage Therapy. Viruses, [S. l.], v. 15, n.4: 1020, abr. 2023. DOI: 10.3390/v15041020. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146840/. Acesso em: 06 set. 2024.
JASSIM, S. A.; LIMOGES, R. G. Natural solution to antibiotic resistance: bacteriophages 'The Living Drugs'. World Jounal Microbiology Biotechnology, [S. l.], v. 30, n. 8, p. 2153-2170, ago. 2014. DOI: 10.1007/s11274-014-1655-7. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072922/. Acesso em: 10 abr. 2024.
JAULT, P. et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infectious Disease, [S. l.], v. 19, p. 35-45, jan. 2019. DOI: 10.1016/S1473-3099(18)30482-1. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30292481/. Acesso em: 20 set. 2024.
KAKASIS, A.; PANITSA, G. Bacteriophage therapy as an alternative treatment for human infections. A comprehensive review. International Journal of Antimicrobial Agents, [S. l.], v. 53, n. 1, p. 16-21, jan. 2019. DOI: 10.1016/j.ijantimicag.2018.09.004. Disponível em: https://www.sciencedirect.com/science/article/abs/pii/S0924857918302632?via%3Dihub. Acesso em: 10 abr. 2024.
LEITNER, L. et al. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infectious Disease, [S. l.], v. 21, n. 3, p. 427-436, mar. 2021. DOI: 10.1016/S1473-3099(20)30330-3. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32949500/. Acesso em: 18 set. 2024.
LUONG, T.; SALABARRIA, A.C.; ROACH, D.R. Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going? Clinical Theraphy, [S. l.], v. 42, n. 9, p. 1659-1680, set. 2020. DOI: 10.1016/j.clinthera.2020.07.014. Disponível em: https://www.clinicaltherapeutics.com/article/S0149-2918(20)30348-9/fulltext. Acesso em: 11 maio 2024.
MALIK, D. J. et al. Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Advances in Colloid and Interface Science, [S. l.], v.249, p. 100-133, nov. 2017. DOI: 10.1016/j.cis.2017.05.014. Disponível em: https://www.sciencedirect.com/science/article/pii/S000186861630392X?via%3Dihub. Acesso em: 16 dez. 2024.
MARCUK, L. M. et al. Clinical studies of the use of bacteriophage in the treatment of cholera. Bulletin of the World Health Organization, [S. l.], v. 45, n. 1, p. 77-83, 1971. Disponível em: https://pubmed.ncbi.nlm.nih.gov/4946956/. Acesso em: 14 out. 2024.
MUTEEB, et al. Origin of Antibiotics and Antibiotic Resistance, and Their Impacts on Drug Development: A Narrative Review. Pharmaceuticals (Basel), [S. l.], v. 16, n. 11, p. 1615, nov. 2023. DOI: 10.3390/ph16111615. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675245/ Acesso em: 28 ago. 2024.
OMS - ORGANIZAÇÃO MUNDIAL DA SAÚDE. Global antimicrobial resistance and use surveillance systems | Country Profiles. [S. l.]: Global Health Observatory, 2019. Disponível em: https://www.who.int/data/gho/data/themes/topics/global-antimicrobial-resistance-surveillance-system-glass/glass-country-profiles. Acesso em: 18 set. 2024
OMS - ORGANIZAÇÃO MUNDIAL DE SAÚDE. Antimicrobial resistance: global report on surveillance. Geneva: World Health Organization, 2014. Disponível em: https://www.who.int/publications/i/item/9789241564748. Acesso em: 04 nov. 2024.
OMS - ORGANIZAÇÃO MUNDIAL DE SAÚDE. Bacterial Priority Pathogens List, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024. Disponível em: https://www.who.int/publications/i/item/9789240093461. Acesso em: 29 ago. 2024.
OMS - ORGANIZAÇÃO MUNDIAL DE SAÚDE. Incentivising the development of new antibacterial treatments 2023. [S. l.]: Global AMR R&D Hub & WHO, 2023. Disponível em: https://cdn.who.int/media/docs/default-source/antimicrobial-resistance/amr-gcp-irc/incentivising-development-of-new-antibacterial-treatments-2023---progress-report.pdf?sfvrsn=72e4f738_3. Acesso em: 11 mai. 2024.
PARDO-FREIRE, M.; DOMINGO-CALAP, P. Phages and Nanotechnology: New Insights against Multidrug-Resistant Bacteria. Biodesingn Research, [S. l.], v.5, p. 1-13, jan, 2023. DOI: 10.34133/bdr.0004. Disponível em: https://pmc.ncbi.nlm.nih.gov/articles/PMC10521656/. Acesso em: 16 dez. 2024.
PELFRENE, E. et al. Bacteriophage therapy: a regulatory perspective. Journal of Antimicrobial Chemotherapy, [S. l.], v. 71, n. 8, p. 2071-2074, ago.2016. DOI: https://doi.org/10.1093/jac/dkw083. Disponível em: https://academic.oup.com/jac/article/71/8/2071/2237822?login=false. Acesso em: 20 set. 2024.
PIRNAY, J. et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nature Microbiology, [S. l.], v. 9, p. 1434-1453, jun. 2024. DOi: https://doi.org/10.1038/s41564-024-01705-x. Disponível em: https://www.nature.com/articles/s41564-024-01705-x. Acesso em: 20 set. 2024.
PIRNAY, J. Phage Therapy in the Year 2035. Frontiers Microbiology, [S. l.], v. 11, n. 1171, jun. 2020. DOI: 10.3389/fmicb.2020.01171. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284012/. Acesso em: 14 out. 2024.
RODRIGUEZ, J. M. et al. Case Report: successful use of phage therapy in refractory MRSA chronic rhinosinusitis. International Journal of Infectious Diseases, [S. l.], v. 121, p. 14-16, ago. 2022. DOI: 10.1016/j.ijid.2022.04.049. Disponível em: https://www.ijidonline.com/article/S1201-9712(22)00247-8/fulltext. Acesso em: 18 set. 2024.
RUBALSKII, E. et al. Bacteriophage Therapy for Critical Infections Related to Cardiothoracic Surgery. Antibiotics (Basel), [S. l.], v.9, n. 5:232, mai. 2020. DOI: 10.3390/antibiotics9050232. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7277081/. Acesso em: 28 ago. 2024.
SABINO, Y. N. V. et al. Characterization of antibiotic resistance genes in the species of the rumen microbiota. Nature Comumunications, [S. l.], v. 10, n. 5252, p. 1-11, nov. 2019. DOI: 10.1038/s41467-019-13118-0. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868206/. Acesso em: 01 mai. 2024.
SARKER, S. A. et al. Oral Phage Therapy of Acute Bacterial Diarrhea With Two Coliphage Preparations: A Randomized Trial in Children From Bangladesh. eBioMedicine, [S. l.], v. 4, p. 124-137, feb. 2016. DOI: 10.1016/j.ebiom.2015.12.023. Disponível em: https://pubmed.ncbi.nlm.nih.gov/26981577/. Acesso em: 20 set. 2024.
SARKER, S. A. et al. Oral T4-like phage cocktail application to healthy adult volunteers from Bangladesh. Virology, [S. l.], v 434, n. 2, p. 222-232, jan. 2012. DOI: 10.1016/j.virol.2012.09.002. Disponível em: https://www.sciencedirect.com/science/article/pii/S0042682212004436?pes=vor. Acesso em: 20 set. 2024.
SLOPEK, S. et al. Results of bacteriophage treatment of suppurative bacterial infections. III. Detailed evaluation of the results obtained in further 150 cases. Archivum Immunologiae et Therapiae Experimentalis (Warsz), [S. l.], v. 32, n. 3, p. 317-335, 1984. Disponível em: https://pubmed.ncbi.nlm.nih.gov/6395825/. Acesso em: 14 out. 2024.
SLOPEK, S. et al. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of the results obtained in 370 cases Archivum Immunologiae et Therapiae Experimentalis (Warsz), [S. l.], v. 33, n. 2, p. 219-240, 1985. Disponível em: https://pubmed.ncbi.nlm.nih.gov/2935115/. Acesso em: 14 out. 2024.
SLOPEK, S. et al. Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Archivum Immunologiae et Therapiae Experimentalis (Warsz), [S. l.], v. 33, n. 2, p. 219-240, 1985. Disponível em: https://pubmed.ncbi.nlm.nih.gov/2935116/. Acesso em: 14 out. 2024.
SLOPEK, S. et al. Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Archivum Immunologiae et Therapiae Experimentalis (Warsz), [S. l.], v. 33, n. 2, p. 261-273, 1985. Disponível em: https://pubmed.ncbi.nlm.nih.gov/2935117/. Acesso em: 14 out. 2024.
SMOLINSKI, M. S.; HAMBURG, M. A.; LEDERBERG, J. Microbial Threats to Health: Emergence, Detection, and Response. Washington: The National Academies Press, 2003. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK221483/#ddd00042. Acesso em: 28 fev. 2024.
STRATHDEE, S. A. et al. Phage therapy: From biological mechanisms to future directions. Cell, [S. l.], v. 186, n. 1, p. 17-31, jan. 2023. DOI: 10.1016/j.cell.2022.11.017. Disponível em: https://www.cell.com/cell/fulltext/S00928674(22)014611?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867422014611%3Fshowall%3Dtrue. Acesso em: 21 abr. 2024.
SUH, G. A. et al. Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrobial Agents and Chemotheraphy, [S. l.], v. 66, n. 3, mar. 2022. DOI: 10.1128/AAC.02071-21. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923208/. Acesso em: 20 set. 2024.
SUTCLIFFE, S. G; REYES, A.; MAURICE, C. F. Bacteriophages playing nice: Lysogenic bacteriophage replication stable in the human gut microbiota. IScience, [S. l.], v. 26, n. 2, p. 1-14, fev. 2023. DOI: https://doi.org/10.1016/j.isci.2023.106007. Disponível em: https://www.cell.com/iscience/fulltext/S2589-0042(23)00084-6#%20. Acesso em: 11 maio 2024.
VIERTEL, T. M.; RITTER, K., HORZ, H. Viruses versus bacteria—novel approaches to phage therapy as a tool against multidrug-resistant pathogens. Journal of Antimicrobial Chemotherapy, [S. l.], v. 69, p. 2326-2336, mai. 2014. DOI: 10.1093/jac/dku173. Disponível em: https://academic.oup.com/jac/article/69/9/2326/2911275?login=false. Acesso em: 18 maio 2024.
WRIGHT, A. et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clinical Otolaryngology, [S. l.], v. 34, n. 4 p. 349-457, ago. 2009. DOI: 10.1111/j.1749-4486.2009.01973.x. Disponível em: https://onlinelibrary.wiley.com/doi/10.1111/j.1749-4486.2009.01973.x. Acesso em: 06 set. 2024.
Downloads
Publicado
Licença
Copyright (c) 2025 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
